<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37559726</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Divergent adaptive immune responses define two types of long COVID.</ArticleTitle><Pagination><StartPage>1221961</StartPage><MedlinePgn>1221961</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1221961</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1221961</ELocationID><Abstract><AbstractText Label="BACKGROUND">The role of adaptive immune responses in long COVID remains poorly understood, with contrasting hypotheses suggesting either an insufficient antiviral response or an excessive immune response associated with inflammatory damage. To address this issue, we set to characterize humoral and CD4+ T cell responses in long COVID patients prior to SARS-CoV-2 vaccination.</AbstractText><AbstractText Label="METHODS">Long COVID patients who were seropositive (LC+, n=28) or seronegative (LC-, n=23) by spike ELISA assay were recruited based on (i) an initial SARS-CoV-2 infection documented by PCR or the conjunction of three major signs of COVID-19 and (ii) the persistence or resurgence of at least 3 symptoms for over 3 months. They were compared to COVID patients with resolved symptoms (RE, n=29) and uninfected control individuals (HD, n=29).</AbstractText><AbstractText Label="RESULTS">The spectrum of persistent symptoms proved similar in both long COVID groups, with a trend for a higher number of symptoms in the seronegative group (median=6 <i>vs</i> 4.5; P=0.01). The use a highly sensitive S-flow assay enabled the detection of low levels of SARS-CoV-2 spike-specific IgG in 22.7% of ELISA-seronegative long COVID (LC-) patients. In contrast, spike-specific IgG levels were uniformly high in the LC+ and RE groups. Multiplexed antibody analyses to 30 different viral antigens showed that LC- patients had defective antibody responses to all SARS-CoV-2 proteins tested but had in most cases preserved responses to other viruses. A sensitive primary T cell line assay revealed low but detectable SARS-CoV-2-specific CD4 responses in 39.1% of LC- patients, while response frequencies were high in the LC+ and RE groups. Correlation analyses showed overall strong associations between humoral and cellular responses, with exceptions in the LC- group.</AbstractText><AbstractText Label="CONCLUSIONS">These findings provide evidence for two major types of antiviral immune responses in long COVID. Seropositive patients showed coordinated cellular and humoral responses at least as high as those of recovered patients. In contrast, ELISA-seronegative long COVID patients showed overall low antiviral responses, with detectable specific CD4+ T cells and/or antibodies in close to half of patients (52.2%). These divergent findings in patients sharing a comparable spectrum of persistent symptoms raise the possibility of multiple etiologies in long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Kervevan, Staropoli, Slama, Jeger-Madiot, Donnadieu, Planas, Pietri, Loghmari-Bouchneb, Alaba Tanah, Robinot, Boufassa, White, Salmon-Ceron and Chakrabarti.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kervevan</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staropoli</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slama</LastName><ForeName>Dorsaf</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, H&#xf4;tel Dieu Hospital, Assistance Publique-H&#xf4;pitaux de Paris, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeger-Madiot</LastName><ForeName>Rapha&#xeb;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnadieu</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Disease Analytics and Epidemiology G5 Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planas</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietri</LastName><ForeName>Marie-Pierre</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, H&#xf4;tel Dieu Hospital, Assistance Publique-H&#xf4;pitaux de Paris, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loghmari-Bouchneb</LastName><ForeName>Wiem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, H&#xf4;tel Dieu Hospital, Assistance Publique-H&#xf4;pitaux de Paris, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alaba Tanah</LastName><ForeName>Motolete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, H&#xf4;tel Dieu Hospital, Assistance Publique-H&#xf4;pitaux de Paris, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinot</LastName><ForeName>R&#xe9;my</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boufassa</LastName><ForeName>Faroudy</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM U1018, Center for Research in Epidemiology and Population Health (CESP), Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Disease Analytics and Epidemiology G5 Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon-Ceron</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, H&#xf4;tel Dieu Hospital, Assistance Publique-H&#xf4;pitaux de Paris, Universit&#xe9; de Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Universit&#xe9; de Paris Cit&#xe9;, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell</Keyword><Keyword MajorTopicYN="N">common cold coronavirus</Keyword><Keyword MajorTopicYN="N">humoral immune response</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">seronegative and seropositive</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37559726</ArticleId><ArticleId IdType="pmc">PMC10408302</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1221961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med (2022) 28(5):911&#x2013;23. doi: 10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-c-. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis (2022) 22(4):e102&#x2013;e7. doi: 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M, Wang R, Yu H, Spatz ES, Montoy JC, Rodriguez R, et al. . Severe fatigue and persistent symptoms at three months following SARS-CoV-2 infections during the pre-delta, delta, and omicron time periods: a multicenter prospective cohort study. Clin Infect Dis (2023) 76:1930&#x2013;1941. doi: 10.1093/cid/ciad045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol (2023) 21(3):133&#x2013;46. doi: 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife (2023) 12:e86014. doi: 10.7554/eLife.86002</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA (2020) 324(6):603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open (2021) 4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, et al. . Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: a cross-sectional study. J Infect (2021) 82(2):e1&#x2013;4. doi: 10.1016/j.jinf.2020.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7833274</ArticleId><ArticleId IdType="pubmed">33285216</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? Nat Rev Immunol (2021) 21(12):762&#x2013;8. doi: 10.1038/s41577-021-00631-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00631-x</ArticleId><ArticleId IdType="pmc">PMC8525456</ArticleId><ArticleId IdType="pubmed">34667307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. . Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep (2021) 11(1):13153. doi: 10.1038/s41598-021-92045-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92045-x</ArticleId><ArticleId IdType="pmc">PMC8222239</ArticleId><ArticleId IdType="pubmed">34162913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. . Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med (2023) 183(6):566&#x2013;80. doi: 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont R, Richard V, Lorthe E, Loizeau A, Pennacchio F, Zaballa ME, et al. . A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents. Nat Commun (2022) 13(1):7086. doi: 10.1038/s41467-022-34616-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34616-8</ArticleId><ArticleId IdType="pmc">PMC9708639</ArticleId><ArticleId IdType="pubmed">36446760</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis (2021) 22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun (2022) 103:154&#x2013;62. doi: 10.1016/j.bbi.2022.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med (2022) 28(11):2398&#x2013;405. doi: 10.1038/s41591-022-02051-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau O, Zins M, Touvier M, Wiernik E, Lemogne C, de Lamballerie X, et al. . Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Netw Open (2022) 5(11):e2240985. doi: 10.1001/jamanetworkopen.2022.40985</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.40985</ArticleId><ArticleId IdType="pmc">PMC9647489</ArticleId><ArticleId IdType="pubmed">36350653</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Nieters A, Krausslich HG, Brockmann SO, Gopel S, Kindle G, et al. . Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ (2022) 379:e071050. doi: 10.1136/bmj-2022-071050</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071050</ArticleId><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert CR, Strahm C, G&#xfc;sewell S, Cusini A, Brucher A, Goppel S, et al. . Post-acute sequelae after SARS-CoV-2 infection by viral variant and vaccination status: a multicenter cross-sectional study. Clin Infect Dis (2023), ciad143. doi:&#xa0;10.1093/cid/ciad143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. Bmj (2021) 372:n405. doi: 10.1136/bmj.n405</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n405</ArticleId><ArticleId IdType="pubmed">33568362</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. . SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature (2022) 612(7941):758&#x2013;63. doi: 10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. . COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med (2021) 13(596):eabf8396. doi: 10.1126/scitranslmed.abf8396</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci (2020) 24:168&#x2013;75. doi: 10.1101/2020.06.04.135012</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.04.135012</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, et al. . Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut (2021) 71(1):226&#x2013;29. doi: 10.1101/2020.10.28.20219014</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.28.20219014</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, et al. . Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology (2022) 163(2):495&#x2013;506 e8. doi: 10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis (2021) 224(11):1839&#x2013;48. doi: 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Zapata E, Ramirez-Santana C, et al. . Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis (2022) 225(12):2155&#x2013;62. doi: 10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. . Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis (2021) 8(6): ofab156. doi: 10.1093/ofid/ofab156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. . The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med (2022) 3(6):100663. doi:&#xa0;10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23(2):210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long-COVID. Int J Infect Dis (2021) 112:217&#x2013;26. doi: 10.1016/j.ijid.2021.09.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. . Distinguishing features of long COVID identified through immune profiling. medRxiv (2022). doi: 10.1101/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. . Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol (2021) 6(65):eabk1741. doi: 10.1126/sciimmunol.abk1741</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Galan M, Vigon L, Fuertes D, Murciano-Anton MA, Casado-Fernandez G, Dominguez-Mateos S, et al. . Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol (2022) 13:848886. doi: 10.3389/fimmu.2022.848886</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.848886</ArticleId><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Sarkar S, Fram TR, Boppana S, Sterrett S, Qin K, et al. . Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight (2021) 6(15):e151544. doi: 10.1172/jci.insight.151544</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, Peluso MJ, Thomas R, Shin M-G, Neidleman J, Luo X, et al. . Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv (2023). 2023.02.09.527892. doi: 10.1101/2023.02.09.527892</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.09.527892</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185(5):881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. . Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest (2023) 133(3):e163669. doi: 10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Getts DR, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev (2013) 255(1):197&#x2013;209. doi: 10.1111/imr.12091</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12091</ArticleId><ArticleId IdType="pmc">PMC3971377</ArticleId><ArticleId IdType="pubmed">23947356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun (2021) 4:100100. doi: 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (2022) 375(6585):1122&#x2013;7. doi: 10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Muri J, Cecchinato V, Cavalli A, Shanbhag AA, Matkovic M, Biggiogero M, et al. . Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat Immunol (2023) 24(4):604&#x2013;11. doi:&#xa0;10.1038/s41590-023-01445-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01445-w</ArticleId><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="pubmed">36879067</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. Bmj (2021) 374:n1648. doi: 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Lampe J, Muller-Fielitz H, Schuster R, Zille M, Muller K, et al. . The SARS-CoV-2 main protease m(pro) causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci (2021) 24(11):1522&#x2013;33. doi: 10.1038/s41593-021-00926-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00926-1</ArticleId><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Layne SP, Walters KA, Kash JC, Taubenberger JK. More autopsy studies are needed to understand the pathogenesis of severe COVID-19. Nat Med (2022) 28(3):427&#x2013;8. doi: 10.1038/s41591-022-01684-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01684-8</ArticleId><ArticleId IdType="pmc">PMC8940687</ArticleId><ArticleId IdType="pubmed">35177863</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, et al. . SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep (2021) 41(8):BSR20210611. doi: 10.1042/BSR20210611</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. . Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond) (2020) 21(1):e63&#x2013;7. doi: 10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. . (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021) 48(9):2823&#x2013;33. doi: 10.1007/s00259-021-05215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul BD, Lemle MD, Komaroff AL, Snyder SH. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci USA (2021) 118(34):e2024358118. doi: 10.1073/pnas.2024358118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. . Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med (2023) 29(1):226&#x2013;35. doi: 10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep (2021) 34(6):108728. doi: 10.1016/j.celrep.2021.108728</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108728</ArticleId><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. . Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell (2020) 183(4):996&#x2013;1012.e19. doi:&#xa0;10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature (2021) 601(7891):110&#x2013;7. doi: 10.1101/2021.06.26.21259239</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.26.21259239</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Lemogne C, Felten R, Sibilia J. Excess of post-acute sequelae of COVID-19 after the first wave of the pandemic. Infect Dis Ther (2022) 11(6):2279&#x2013;85. doi: 10.1007/s40121-022-00698-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00698-6</ArticleId><ArticleId IdType="pmc">PMC9511440</ArticleId><ArticleId IdType="pubmed">36156194</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna BA, Lim EY, Mactavous L, Team NB, Lyons PA, Doffinger R, et al. . Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. EBioMedicine (2022) 81:104129. doi: 10.1016/j.ebiom.2022.104129</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104129</ArticleId><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="pubmed">35772216</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon D, Slama D, Linard F, Dumesges N, Lebaut V, Hakim F, et al. . Factors associated with release relief of long COVID symptoms at 12-months and their impact on daily life. medRxiv (2022). 2022.11.18.22282459. doi: 10.1101/2022.11.18.22282459</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.18.22282459</ArticleId></ArticleIdList></Reference><Reference><Citation>Slama D, Ben Azaiez M, Robineau O, Le Baut V, de Broucker T, Hautefort C, et al. . Pr&#xe9;sentation clinique des patients pr&#xe9;sentant des sympt&#xf4;mes persistants apr&#xe8;s un &#xe9;pisode document&#xe9; ou non document&#xe9; d&#x2019;infection par le SARS-CoV-2. Infect Dis Now (2021) 51(5 Supplement):S72.</Citation></Reference><Reference><Citation>Wei J, Matthews PC, Stoesser N, Maddox T, Lorenzi L, Studley R, et al. . Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun (2021) 12(1):6250. doi: 10.1038/s41467-021-26479-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26479-2</ArticleId><ArticleId IdType="pmc">PMC8556331</ArticleId><ArticleId IdType="pubmed">34716320</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen CK, Rezahosseini O, Gybel-Brask M, Kristensen JH, Hasselbalch RB, Pries-Heje MM, et al. . Risk factors for being seronegative following SARS-CoV-2 infection in a Large cohort of health care workers in Denmark. Microbiol Spectr. (2021) 9(2):e0090421. doi: 10.1128/Spectrum.00904-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00904-21</ArticleId><ArticleId IdType="pmc">PMC8528102</ArticleId><ArticleId IdType="pubmed">34668738</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. . Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2. J Infect Dis (2021) 224(6):983&#x2013;8. doi: 10.1093/infdis/jiab127</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab127</ArticleId><ArticleId IdType="pmc">PMC7989436</ArticleId><ArticleId IdType="pubmed">33693749</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. . A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med (2020) 12(559):eabc3103. doi: 10.1126/scitranslmed.abc3103</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc3103</ArticleId><ArticleId IdType="pmc">PMC7665313</ArticleId><ArticleId IdType="pubmed">32817357</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith N, Goncalves P, Charbit B, Grzelak L, Beretta M, Planchais C, et al. . Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat Immunol (2021) 22(11):1428&#x2013;39. doi: 10.1038/s41590-021-01028-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01028-7</ArticleId><ArticleId IdType="pmc">PMC8553615</ArticleId><ArticleId IdType="pubmed">34471264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, et al. . Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection. J Infect Dis (2021) 224(9):1489&#x2013;99. doi: 10.1093/infdis/jiab375</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab375</ArticleId><ArticleId IdType="pmc">PMC8420633</ArticleId><ArticleId IdType="pubmed">34282461</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Sidney J, Vita R, Peters B, Crotty S, Weiskopf D, et al. . SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe (2021) 29(7):1076&#x2013;92. doi: 10.1016/j.chom.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8139264</ArticleId><ArticleId IdType="pubmed">34237248</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature (2020) 584(7821):457&#x2013;62. doi: 10.1038/s41586-020-2550-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Heide J, Schulte S, Kohsar M, Brehm TT, Herrmann M, Karsten H, et al. . Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. PloS Pathog (2021) 17(9):e1009842. doi: 10.1371/journal.ppat.1009842</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009842</ArticleId><ArticleId IdType="pmc">PMC8445433</ArticleId><ArticleId IdType="pubmed">34529740</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, et al. . Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med (2021) 2(2):100204. doi: 10.1016/j.xcrm.2021.100204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med (2022) 70(1):61&#x2013;7. doi: 10.1136/jim-2021-002051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray SM, Ansari AM, Frater J, Klenerman P, Dunachie S, Barnes E, et al. . The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol (2022) 23:304&#x2013;16. doi:&#xa0;10.1038/s41577-022-00809-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00809-x</ArticleId><ArticleId IdType="pmc">PMC9765363</ArticleId><ArticleId IdType="pubmed">36539527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Keshet A, Graham MS, Joshi AD, Shilo S, Rossman H, et al. . Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study. Lancet Digit Health (2021) 3(9):e577&#x2013;e86. doi: 10.1016/S2589-7500(21)00115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(21)00115-1</ArticleId><ArticleId IdType="pmc">PMC8297994</ArticleId><ArticleId IdType="pubmed">34305035</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol (2017) 140(4):909&#x2013;20. doi: 10.1016/j.jaci.2017.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC7173222</ArticleId><ArticleId IdType="pubmed">28987220</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur (2021) 6:100122. doi: 10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (2021) 371(6529):eabf4063. doi: 10.1126/science.abf4063</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks R, Lau WW, Liu C, Han KL, Vrindten KL, Sun G, et al. . Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. Nature (2023) 614(7949):752&#x2013;61. doi: 10.1038/s41586-022-05670-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05670-5</ArticleId><ArticleId IdType="pmc">PMC10481789</ArticleId><ArticleId IdType="pubmed">36599369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>